Study Finds 99.6% of Statin Users Face Under 10% 10-Year Muscle-Disorder Risk
Updated
Updated · Neurology Advisor · Jul 13
Study Finds 99.6% of Statin Users Face Under 10% 10-Year Muscle-Disorder Risk
3 articles · Updated · Neurology Advisor · Jul 13
Summary
99.6% of patients in an external validation cohort had a predicted 10-year risk below 10% for serious muscle disorders linked to statin treatment, according to a Lancet study.
5.7 million people were analyzed across derivation and validation cohorts as Oxford researchers built a 22-predictor model using electronic health records for adults eligible for statins.
The model estimated risks of muscle disorders tied to hospitalization or death and showed solid performance in external validation, with a 10-year C-index of 0.782.
Researchers said the tool could improve statin decision-making by quantifying a rare but widely feared side effect and reassuring most patients who may benefit from treatment.